Lexaria赞扬Eli Lilly的Foundayo药物获批-动脉网

Lexaria Applauds Eli Lilly's Foundayo Drug Approval

INN 等信源发布 2026-04-07 23:21



可切换为仅中文







Investing News Network

投资新闻网络

April 07, 2026

2026年4月7日

The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects

口服减肥/糖尿病药物治疗的数量正在增加，减少副作用的需求也随之增加。

KELOWNA, BC /

基洛纳，不列颠哥伦比亚省 /

ACCESS Newswire

ACCESS 新闻专线

/ April 7, 2026 /

2026年4月7日

Lexaria Bioscience Corp.

Lexaria生物科学公司

(Nasdaq:

（纳斯达克：

LEXX

莱克斯

), (the 'Company' or 'Lexaria'), a global innovator in drug delivery platforms is pleased to recognize that the US Food and Drug Administration ('FDA') has approved Eli Lilly and Company's

），（“公司”或“Lexaria”），一家全球药物递送平台的创新者，欣然认可美国食品药品监督管理局（“FDA”）已批准Eli Lilly and Company的

Foundayo

基金会

™

glucagon-like peptide-1 ('GLP-1') agonist (orforglipron) oral tablet for adult use in controlling obesity and weight-related medical conditions.

胰高血糖素样肽-1（“GLP-1”）受体激动剂（奥福格列波隆）口服片剂，用于成人控制肥胖及与体重相关的医疗状况。

'This latest approval from the FDA expands choices for Americans searching for the right weight control drug that best suits their needs,' said Richard Christopher, CEO of

“这次FDA的最新批准为寻找最适合自身需求的减肥药的美国人提供了更多选择，”首席执行官理查德·克里斯托弗表示，

Lexaria Bioscience Corp.

莱克萨里亚生物科学公司

'Expanded choices within the historically limited oral weight-loss drug category increases opportunities for Lexaria to partner with the leading companies in the pharmaceutical industry to implement DehydraTECH

“在历史上有限的口服减肥药物类别中，选择的增加为Lexaria与制药行业的领先公司合作实施DehydraTECH技术提供了更多机会。

™

technology to improve patient experiences including through the potential for reduced side effects.'

技术改善患者体验，包括减少副作用的潜力。

The recent FDA approval of Foundayo

最近FDA批准了Foundayo

™

follows both the December 2025 approval of Wegovy

继2025年12月Wegovy获批之后

tablets for weight loss and the September 2019 approval of Rybelsus® tablets for diabetes, bringing the total number of FDA approved GLP-1 oral brand offerings to 3. In 2025, worldwide revenues of the sole oral offering within the GLP-1 category (Rybelsus

用于减肥的片剂和2019年9月获批的糖尿病药物Rybelsus®片剂，使得FDA批准的GLP-1口服品牌药物总数达到3种。到2025年，GLP-1类别的唯一口服药物（Rybelsus）的全球收入将达到...

) totaled $3.5B. This represented less than 5% of the 2025 worldwide GLP-1 revenue total, highlighting the tremendous upside growth potential that oral options have within the GLP-1 marketplace.

）总计达 35 亿美元。这还不到 2025 年全球 GLP-1 收入总额的 5%，突显了口服药物在 GLP-1 市场中巨大的增长潜力。

As Lexaria

作为Lexaria

recently announced

最近宣布的

, its forward-looking strategic plans for the GLP-1 sector continue to be centered around improving the patient experience while using these drugs for indications including but not limited to diabetes and weight loss, primarily through the reduction of unwanted side effects.

，其针对GLP-1领域的前瞻性战略计划继续围绕改善患者在使用这些药物治疗包括但不限于糖尿病和减肥在内的适应症时的体验，主要通过减少不良副作用来实现。

In Eli Lilly's clinical trial

在礼来公司的临床试验中

, patients taking Foundayo

，服用Foundayo的患者

™

(orforglipron) for the full study duration of 72-weeks lost an average of 27.3 pounds (12.4%). One of Foundayo's™ biggest advantages over Novo Nordisk's existing Wegovy

在为期72周的完整研究期间，（orforglipron）平均减重27.3磅（12.4%）。Foundayo™相较于诺和诺德现有的Wegovy，最大的优势之一在于

™

(semaglutide) oral medication is that Foundayo

（司美格鲁肽）口服药物是Foundayo。

™

can be taken at any time of day regardless of eating habits, whereas Wegovy™ tablets must be taken only on an empty stomach 30 minutes before breakfast. Notwithstanding this and as

可以在一天中的任何时间服用，不受饮食习惯的影响，而Wegovy™药片则必须在早餐前30分钟空腹服用。尽管如此，并且如

reported by Scientific American

据《科学美国人》报道

, 'Orforglipron showed higher rates of

，‘Orforglipron显示出更高的比率

adverse side effects

不良副作用

such as nausea, vomiting and other gastrointestinal issues compared with semaglutide. More people discontinued orforglipron during the trial than those who stopped taking semaglutide, too'.

例如，与司美格鲁肽相比，奥尔福格里普隆出现了恶心、呕吐和其他胃肠道问题。在试验期间，停止使用奥尔福格里普隆的人数也比停止使用司美格鲁肽的人数多。

According to Eli Lilly, 'The most common side effects of Foundayo

根据礼来公司介绍，“Foundayo最常见的副作用是

™

include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo.'

包括恶心、便秘、腹泻、呕吐、消化不良、胃（腹部）疼痛、头痛、腹部肿胀、感觉疲倦、打嗝、胃灼热、胀气和脱发。这些并非 Foundayo 的所有可能副作用。

In various studies performed during the past ~2 years, DehydraTECH has already been evaluated orally with semaglutide, liraglutide, and tirzepatide and has successfully reduced side effects with each drug. For example, in Study GLP-1-H24-4,

在过去的约两年中进行的多项研究中，DehydraTECH已经通过口服方式与司美鲁肽、利拉鲁肽和替西帕肽进行了评估，并成功减少了每种药物的副作用。例如，在研究GLP-1-H24-4中，

Lexaria reported a 47.9% reduction

Lexaria 报告称减少了 47.9%

in the total quantity of adverse events derived from oral DehydraTECH-semaglutide vs. Rybelsus

在口服DehydraTECH-semaglutide与Rybelsus产生的不良事件总量中

™

。

Lexaria has also

莱克萨里亚也

announced plans

宣布计划

to conduct DehyrdaTECH-processed GLP-1 testing in 2026 with additional GLP-1 drugs not previously evaluated, including retatrutide and amycretin, and is considering testing DehydraTECH-processed orforglipron as well. Lexaria believes that reducing adverse events in the GLP-1 drug sector is a significant competitive advantage enjoyed by DehydraTECH technology, which is now backed by 65 issued patents around the world..

将于2026年进行DehyrdaTECH处理的GLP-1测试，包括之前未评估过的其他GLP-1药物，如雷塔鲁肽和艾米克雷汀，并考虑测试DehydraTECH处理的奥尔福格利普隆。Lexaria认为，减少GLP-1药物领域的不良反应是DehydraTECH技术的一项重要竞争优势，该技术现已获得全球65项已颁发专利的支持。

About

关于

Lexaria Bioscience Corp.

Lexaria生物科学公司

& DehydraTECH

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier.

DehydraTECH™ 是 Lexaria 旗下的专利药物递送配方和加工平台技术，通过口服递送方式改善多种药物进入血液的方式。DehydraTECH 已多次证明其能够提高生物吸收率、减少副作用，并更有效地将某些药物递送到血脑屏障。

Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit .

Lexaria 拥有一个经许可的内部研究实验室，并持有强大的知识产权组合，在全球范围内已获得65项专利，还有更多专利正在申请中。欲了解更多信息，请访问。

www.lexariabioscience.com

。

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

关于前瞻性声明的注意事项

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as 'anticipate,' 'if,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'could,' 'should,' 'will,' and other similar expressions.

本新闻稿包含前瞻性陈述。这些陈述是根据适用的证券法定义的。这些陈述可以通过诸如“预期”、“如果”、“相信”、“计划”、“估计”、“预计”、“意图”、“可能”、“可以”、“应该”、“将”以及其他类似表达来识别。

Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study.

本新闻稿中的前瞻性陈述包括但不限于公司关于本次发行所得款项的预期用途，以及公司执行研究计划、获得监管批准或拨款或从任何研究或研究中体验到积极影响或结果的能力相关的陈述。

Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements.

此类前瞻性陈述是公司基于当前信息的最佳判断估计，涉及若干风险和不确定性，无法保证公司实际能够实现这些前瞻性陈述中披露的计划、意图或预期。

As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the.

因此，你不应过度依赖这些前瞻性声明。可能导致实际结果与公司估计大相径庭的因素包括但不限于：市场及其他条件、政府监管及监管审批、管理与维持增长、负面宣传的影响、诉讼、竞争、科学发现、专利申请与审批流程、使用DehydraTECH技术的产品测试或使用可能引发的潜在不利影响、公司维持现有合作并实现其利益的能力、与疫情或其他原因相关的计划研发可能发生的延迟或取消，以及不时在其他因素中可能识别出的因素。

INVESTOR CONTACT:

投资者联系人：

George Jurcic - Head of Investor Relations

乔治·尤尔契奇 - 投资者关系主管

ir@lexariabioscience.com

Phone: 250-765-6424, ext 202

电话：250-765-6424，分机202

SOURCE:

源：

Lexaria Bioscience Corp.

Lexaria生物科学公司

View the original